Bayer to present latest research on real-world impact of menopause symptoms at IMS 2022
Not intended for U.S. and UK Media – 18th World Congress on Menopause by the International Menopause Society (IMS):
The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating physicians. / This study confirmed vasomotor symptoms (VMS) are considered the most common and distressing menopause symptoms but also showed a high burden of symptoms beyond VMS in menopausal women / It highlights the need for increased awareness and management around menopause symptoms beyond VMS to enhance the dialogue and shared decision-making
Berlin, October 25, 2022 – Bayer will present latest research on menopause symptoms at the upcoming 18th World Congress by the International Menopause Society (IMS), which takes place from October 26 – 29, in Lisboa, Portugal. This data will include key findings from the REALISE study, highlighting the need to broaden the awareness of the scope and impact on menopause beyond vasomotor symptoms (VMS; also referred to as hot flashes) as women frequently experience a range of other symptoms including mood changes, sleep disturbance and vaginal dryness. It shows the importance to broaden the awareness and management around menopause symptoms beyond VMS, and their impact in women’s lives to enhance dialogue and shared decision-making.
As a leader in women’s healthcare, Bayer is dedicated to broadening therapeutic choices and to increase awareness and education around menopause. As part of this commitment, the company is investigating new approaches to broaden its menopause portfolio, to address an important unmet medical need in menopause management as currently a vast majority of women is not receiving treatment for their menopause symptoms.
Bayer’s presentations at the IMS 2022 are:
· #11559 Real-world evaluation of physician-reported symptoms and burden of vasomotor symptoms associated with menopause in the United States and Europe Kingsberg S, Schoof N, Saydam S, Caetano C (Speaker), Janssenswillen C, Small M, Harvey M, Moeller C, Banks V
· #11560 Patient and physician alignment on symptoms of menopause: findings from the real-world REALISE study in the United States and Europe
Kingsberg S, Schoof N, Saydam S, Caetano C (Speaker), Janssenswillen C, Scott M, Lee L, Moeller C, Banks V
The poster session will be held on October 27 h18:50-20:15 CEST.
To view the complete abstracts, please visit IMS Congress Website.
About Vasomotor Symptoms
Vasomotor symptoms (VMS; also referred to as hot flashes) is a result from hyperactivation of the thermoregulatory pathway mediated by hypertrophy of the KNDy neurons due to withdrawal of estradiol, which can result from progressive reduction of ovarian function due to natural menopause or medical intervention by bilateral oophorectomy or endocrine therapy.
VMS are reported by up to 80% of women at some point during the menopausal transition and the leading cause for seeking medical attention during this particular phase of a woman’s life. Over 1/3 of women report severe symptoms, which can last 10 years or more after the last menstrual period, with relevant impact in quality of life.
Vasomotor symptoms can also be caused by endocrine therapy for treatment or prevention of breast cancer impact quality of life and treatment adherence and cannot currently be addressed as no treatment options are available.
By 2030, the world population of women in the menopause phase is projected to increase to 1.2 billion, with 47 million new entrants each year. Menopause is a natural phase in women’s lives, related to progressive decline of ovarian function, which usually occurs in women in their late 40s or early 50s. It can also be the result of surgical or medical treatment, for example for breast cancer. The decline in hormone production by the ovaries can lead to various symptoms, which can dramatically affect a woman’s health, quality of life, consumption of healthcare and work productivity. The most frequently reported and bothersome symptoms during the menopausal transition are VMS, sleep disturbances and mood changes. With increased longevity, menopause management is of growing importance since this is a period where women are at the peak of their life’s activity, personally and professionally. For this reason, maintaining functional ability and good quality of life is extremely relevant from both a healthcare and socio-economic perspective.
About Women’s Healthcare at Bayer
Bayer is a leader in the area of women’s healthcare, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. Today, Bayer’s research and development efforts focus on finding new treatment options for menopause as well as gynecological diseases and include several compounds in various stages of pre-clinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to alter the way that gynecological diseases are treated. Additionally, Bayer intends to provide 100 million women in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.